Dr. Hurvitz on Utilizing CDK4/6 Inhibitors in HR+ Breast Cancer

Sara A. Hurvitz, MD, associate professor, the David Geffen School of Medicine, the University of California, Los Angeles (UCLA), medical oncologist, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director, Santa Monica-UCLA Outpatient Oncology Practices, director, Breast Cancer Clinical Trials Program, UCLA, discusses utilizing CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

When disease progression occurs in a patient with HR-positive disease following treatment with a CDK4/6 inhibitor, multiple therapies are available to this patient, Hurvitz says. However, optimal sequencing strategies for these treatments in this setting are not well known, Hurvitz explains.

Some studies have investigated the inhibition of the PI3K pathway, including the use of agents such as alpelisib (Piqray) in patients whose disease has been previously treated with a CDK4/6 inhibitor, Hurvitz continues. Another agent, apitolisib (GDC-098), has highlighted some of encouraging data regarding PI3K pathway inhibitors, Hurvitz concludes.